medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2022, Number 1

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2022; 39 (1)

Congenital Ewing’s sarcoma, report of a case and review of the literature

Morales-Peralta A, Félix-Félix AK, Covarrubias-Espinoza G, Rodríguez-Florido MA, Barceló-Cuevas LF

Language: Spanish
References: 36
Page: 34-40
PDF size: 212.53 Kb.


ABSTRACT

Ewing’s sarcoma (SE) is the second most common bone tumor in childhood and adolescence that can also arise in soft tissues. It is a highly aggressive tumor with a survival, in high-income countries, of 70% for localized disease, while those with metastatic disease reach only 30%. It is an extremely rare tumor in the neonatal period. The case series report a survival of less than 10%. This article presents the case of a patient with a congenital ES extraosseous, who was completely resected, received chemotherapy and at the date of publication is 24 months under surveillence.


REFERENCES

  1. Carvajal GA, Corrales IF, Garcés S, Rivera, C, TroncosoGA. Tumor neuroectodérmico primitivo periféricoextraesquelético/sarcoma de Ewing metastásicoen un neonato. Rev Salud Bosque [Internet]. 2016;6(1): 79. Disponible en http://revistas.unbosque.edu.co/index.php/RSB/article/view/1807

  2. Gaspar N, Hawkins D, Dirksen U, Lewis I, Ferrari S,Le Deley M, et al. Ewing Sarcoma: Current Managementand Future Approaches Through Collaboration.J Clin Oncol. 2015; 33(27): 3036-3046.

  3. Naomi J Balamuth N, Womer R. Ewing’s sarcoma.Lancet Oncol. 2010; 11: 184-92.

  4. Suvà M, Riggi N, Stehle J, Baumer K, Tercier S, JosephJ, et al. Identification of Cancer Stem Cells inEwing’s Sarcoma. Cancer Res. 2009; 69(5): 1776-1781.

  5. Todorova R. Ewing’s Sarcoma Cancer Stem Cell TargetedTherapy. Curr Stem Cell Res Ther. 2014; 9(1):46-62.

  6. Lessnick S, Ladanyi M. Molecular Pathogenesis ofEwing Sarcoma: New Therapeutic and TranscriptionalTargets. Annu Rev of Pathol. 2012; 7(1): 145-159.

  7. He T, Surdez D, Rantala J, Haapa-Paananen S, BanJ, Kauer M, et al. High-throughput RNAi screen inEwing sarcoma cells identifies leucine rich repeatsand WD repeat domain containing 1 (LRWD1) as aregulator of EWS-FLI1 driven cell viability. Gene.2017; 596: 137-146.

  8. Llombart Bosch A, Machado I, López-Guerrero J. Biomarkersin the Ewing sarcoma family of tumors. CurrentBiomarker Findings. 2014; 4: 81-92.

  9. Ross K, Smyth N, Murawski C, Kennedy J. The Biologyof Ewing Sarcoma. ISRN Oncol. 2013; articleID 799725: 7 páginas.

  10. Tiwari R, Tripathy S, Sharma R. Primitive neuroectodermaltumor of hand and forearm: A rare clinicalentity. HAND (NY ). 2012; 7(3): 306-310.

  11. Grünewald T, Cidre-Aranaz F, Surdez D, TomazouE, de Álava E, Kovar H, et al. Ewing sarcoma. NatRev Dis Primers. 2018; 4(1): 5. doi.10.1038/s41572-018-0003

  12. Abboud A, Masrouha K, Saliba M, Haidar R, Saab R,Khoury N, et al. Extraskeletal Ewing sarcoma: Diagnosis,management and prognosis (Review). OncologyLetters. 2021; 21(5): 354.

  13. Biswas B, Shukla N, Deo S, Agarwala S, SharmaD, Vishnubhatla S, et al. Evaluation of outcome andprognostic factors in extraosseous Ewing sarcoma.Pediatr Blood Cancer. 2014; 61(11): 1925-1931.

  14. Jinkala S, Basu D, Mathath D, Dubashi B, BhaumikA. A Rare Case of Congenital EwingSarcoma/PNET of the Scapula. J Pediatr Hematol Oncol.2014; 36(2): e134-e135.

  15. Atla B, Vara S, Sri S, Vandana G. Congenital extraskeletalEwing’s sarcoma of chest wall—arare case report. Indian J Pathol Microbiol. 2011; 54(4):803-805.

  16. Goyal S, Biswas A, Gupta R, Mohanti B. Congenitalperipheral primitive neuroectodermal tumor: A casetreated successfully with multimodality treatment. JEgypt Natl Canc Inst. 2014; 26(4): 219-224.

  17. Hawkins DS, Bölling T, Dubois S, Hogendoorn PC,Jürgens H, Paulussen M, et al. Sarcoma de Ewing.En: Blaney S, Adamson P, Helman L. Pizzo and Poplack’sPediatric Oncology. 7ª Ed. Philadelphia: LippincottWilliams & Wilki; 2016, pp. 1993-2060.

  18. Dubois S, Gorlick R, Janeway K, Marina N. MalignantBone Tumors. En Lanzkowsky’s Manual of PediatricHematology and Oncology. 6a Ed. ElsevierScience; 2016, pp. 749-758.

  19. Sierrasesúmaga L, Sanjulian M, Aristu T. Familia detumores de Ewing. En: Sierrasesúmaga L, AntillónF. Tratado de Oncología Pediátrica. Enfermedadesmalignas del niño y del adolescente. Madrid: PearsonPrentice Hall; 2006, pp. 617-636.

  20. De Alava E. Ewing Sarcoma, an Update on MolecularPathology with Therapeutic Implications. SurgPathol Clin. 2017; 10(3): 575-585.

  21. De Ioris MA, Prete A, Cozza R, Podda M, ManzittiC, Pession A, et al. Ewing sarcoma of the bone inchildren under 6 years of age. PLoS One. 2013; 8:e53223.

  22. Van den Berg H, Dirksen U, Ranft A, Jürgens H.Ewing tumors in infants. Pediatr Blood Cancer 2008;50(4): 761-764.

  23. Eaton B, Claude L, Indelicato D, Vatner R, Yeh B,Schwarz R, et al. Ewing sarcoma. Pediatr Blood Cancer.2021; 68(S2): e28355. doi: 10.1002/pbc.28355

  24. Choi E, Gardner J, Lucas D, McHugh J, Patel R.Ewing sarcoma. Semin Diagn Pathol. 2014; 31(1):39-47.

  25. Kridis W, Toumi N, Chaari H, Khanfir A, Ayadi K,Keskes H, et al. A Review of Ewing SarcomaTreatment: Is it Still a Subject of Debate? Rev RecentClin Trials. 2017; 12(1): 19-23.

  26. Galyfos G, Karantzikos G, Kavouras N, Sianou A,Palogos K, Filis K. Extraosseous Ewing Sarcoma:Diagnosis, Prognosis and Optimal Management. IndianJ Surg. 2015; 78(1): 49-53.

  27. Juergens C, Weston C, Lewis I, Whelan J, PaulussenM, Oberlin O, et al. Safety assessment of intensiveinduction with vincristine, ifosfamide, doxorubicin,and etoposide (VIDE) in the treatment of Ewing tumorsin the EURO-E.W.I.N.G. 99 clinical trial. PediatrBlood Cancer. 2006; 47(1): 22-29.

  28. Tenneti P, Zahid U, Iftikhar A, Yun S, Sohail A,Warraich Z, et al. Role of High-Dose Chemotherapyand Autologous Hematopoietic Cell Transplantationfor Children and Young Adults with RelapsedEwing’s Sarcoma: A Systematic Review. Sarcoma.2018; 2018: 1-12.

  29. Shen C, Perkins S, Bradley J, Mahajan A, MarcusK. Radiation therapy for infants with cancer. PediatrBlood Cancer. 2021; 68(S2).

  30. Bradley J, Kayton M, Chi Y, Hawkins D, Tian J, BrenemanJ, et al. Treatment Approach and Outcomes inInfants With Localized Rhabdomyosarcoma: A ReportFrom the Soft Tissue Sarcoma Committee of theChildren’s Oncology Group. Int J Radiat Oncol BiolPhys. 2019; 103(1): 19-27.

  31. Mohana Rao P, Shantveer G U, Amit Kumar T, ManasKumar P, Sundaram C. Primary ewings sarcomaof cavernous sinus in an infant: a case report and reviewof literature. Turk Neurosurg. 2013; 23(1): 98-103.

  32. Moore SW, Satge D, Sasco AJ, et al. The epidemiologyof neonatal tumors. Report of an internationalworking group. Pediatr Surg Int. 2003; 19(7): 509-519.

  33. Akçalı M, Yapıcıoğlu H, Akay E, Özlü F, KozanoğluB, Erdoğan K, et al. A congenital soft tissue ewingsarcoma in a newborn patient. Turk J Pediatr. 2017;59(1): 76-9.

  34. Jin S, Jiang X, Zhong L. CongenitalEwing’s Sarcoma/Peripheral Primitive NeuroectodermalTumor: A Case Report and Review of theLiterature. Pediatr Neonatol. 2016; 57(5): 436-439.

  35. 35.Littman P, D’Angio GJ. Radiation therapy in the neonate.Am J Pediatr Hematol Oncol. 1981; 3: 279-85.

  36. Berbel Tornero O, Ferrís i Tortajada J, Donat ColomerJ, Ortega García J, Muñoz Guillén A, VerdeguerMiralles A. Tumores neonatales: características clínicasy terapéuticas. Análisis de 72 casos del hospitalinfantil La Fe de Valencia. An Pediatr (Barc). 2006;65(2): 108-117.




2020     |     www.medigraphic.com